精密类治疗药物:开发N-至C端优化治疗药物,向胆囊托基宁-2受体
Marwa N Rahimi1,2, Alicia Corlett3, Jessica Van Zuylekom4
1Department of Radiopharmaceutical Sciences, Cancer Imaging, The Peter MacCallum Cancer Centre, Victoria 3000, Australia.
Theranostics
|March 20, 2024
概括
研究人员开发了针对胆固醇基因素-2受体 (CCK2R) 的新,用于治疗. 修改显著减少脏吸收,同时保持瘤向,显示临床使用的希望.
科学领域:
- 放射性药物开发的发展.
- 分子成像和分子疗法
- 基于的治疗药物.
背景情况:
- 类药物为神经解剖学应用提供了优势,包括快速目标积累和清除.
- 最初的候选药物[68Ga]Ga-DOTA-GA1对胆固醇基因素-2受体 (CCK2R) 具有很高的结合亲和力,但患有高吸收.
研究的目的:
- 通过解决高吸收,优化领先的治疗性候选人.
- 确定针对CCK2R的新型放射性药物候选剂,其生物分布特征得到改善.
主要方法:
- 结构-活性关系研究,涉及对基架的N端残留物进行修改.
- 在携带CCK2R转移瘤的裸体小鼠中评估改性.
- 活体生物分布研究,以量化组织吸收和保留.
主要成果:
- 用D-Ala3替换D-Glu3产生了两个最佳候选物,即[68Ga]Ga-DOTA-GA12和[68Ga]Ga-DOTA-GA13.
- 这些新的放射性体显示出高的目标-背景比率和增强的瘤保留.
- 与原始相比,观察到吸收的显著四倍减少,以及出色的代谢稳定性.
结论:
- 确定了针对CCK2R的新型放射性药物候选剂.
- 改善的生物分布,以高瘤吸收和减少脏积累为特征,支持它们的临床转化.
- 这些发现代表了针对CCK2R的治疗药物中的重大进步.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.1K
09:06Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Published on: February 3, 2023
1.5K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
162
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
162
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K